Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers

Health Policy

Volumn 96, Issue 3, 2010, Pages 179-190

  Carlson, Josh J ^a   Sullivan, Sean D ^a   Garrison, Louis P ^a   Neumann, Peter J ^b   Veenstra, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Economics; Health policy; Outcomes research; Pay for performance; Reimbursement mechanisms; Risk sharing

Indexed keywords

BETA INTERFERON; BEVACIZUMAB; BOSENTAN; CETUXIMAB; EFALIZUMAB; EZETIMIBE; FLUORODEOXYGLUCOSE F 18; GLATIRAMER; IMATINIB; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; IRINOTECAN; MEMANTINE; METFORMIN; OXALIPLATIN; OXYGEN; PIMECROLIMUS; RANIBIZUMAB; RASAGILINE; RIMONABANT; RISPERIDONE; RITUXIMAB; ROSUVASTATIN; ROTIGOTINE; SIBUTRAMINE; TAXANE DERIVATIVE; TEMOZOLOMIDE; TESTOSTERONE; TETRAHYDROLIPSTATIN; VARENICLINE;

ANGIOPLASTY; AUSTRALIA; CANADA; COCHLEA PROSTHESIS; DATA BASE; DEFIBRILLATOR; EUROPE; FOLLOW UP; HEALTH CARE FINANCING; HEALTH CARE SYSTEM; HEALTH INSURANCE; INFORMATION RETRIEVAL; LYOPHILISATE; MEDICAL TECHNOLOGY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE PRICING; REIMBURSEMENT; REVIEW; STENT; TAXONOMY; TREATMENT DURATION; TREATMENT PLANNING; UNITED STATES; ECONOMICS; HEALTH CARE QUALITY; HUMAN; TREATMENT OUTCOME;

BIOMEDICAL TECHNOLOGY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; QUALITY ASSURANCE, HEALTH CARE; REIMBURSEMENT, INCENTIVE; TREATMENT OUTCOME;

EID: 77954458082     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2010.02.005     Document Type: Review

References (40)

1. Pollack A. Pricing pills by the results. New York Times 2007.
2. Tunis S.R., Pearson S.D. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Affairs (Project Hope) 2006, 25:1218-1230.
3. Green C., Bryant J., Takeda A., Cooper K., Clegg A., Smith A., et al. Evidence Review Group Report commissioned by the NHS R&D HTA Programme on behalf of NICE: bortezomib for the treatment of multiple myeloma patients 2006, Southampton Health Technology Assessments Centre.
4. Chadwick D., Gray R. Shared scheme for assessing drugs for multiple sclerosis: dealing with uncertainties about cost effectiveness of treatments is difficult problem. British Medical Journal (Clinical Research Edition) 2003, 326:1212-1213.
5. Napier J.C., Francis R., Wright G. Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis. British Medical Journal (Clinical Research Edition) 2003, 326:1212.
6. National Institute for Health and Clinical Excellence NICE technology appraisal guidance 129: bortezomib monotherapy for relapsed multiple myeloma 2007, Service NH (Ed.).
7. Whalen J. Europe's drug insurers try pay-for-performance. Wall Street Journal 2007, 1.
8. Center for Medicare and Medicaid Services Coverage with evidence development 2008, Center for Medicare and Medicaid Services.
9. National Institute for Health and Clinical Excellence NICE technology appraisal guidance 129: bortezomib monotherapy for relapsed multiple myeloma 2007.
10. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. The New England Journal of Medicine 2005, 352:2487-2498.
11. The NICE u-turn on Lucentis raises more questions about the UK reimbursement system. The Economist 2008.
12. National Institute for Health and Clinical Excellence Ranibizumab and pegaptanib for the treatment of age-related macular degeneration 2008.
13. Chapman S., Reeve E., Price D., Rajaratnam G., Neary R. Outcomes guarantee for lipid-lowering drugs: results from a novel approach to risk sharing in primary care. British Journal of Cardiology 2004, 11:205-210.
14. Boggild M., Palace J., Barton P., Ben-Shlomo Y., Bregenzer T., Dobson C., et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. British Medical Journal (Clinical Research Edition) 2009, 339:b4677.
15. Pickin M., Cooper C.L., Chater T., O'Hagan A., Abrams K.R., Cooper N.J., et al. The Multiple Sclerosis Risk Sharing Scheme Monitoring Study-early results and lessons for the future. BMC Neurology 2009, 9:1.
16. Tunis S.R., Chalkidou K. Coverage with evidence development: a very good beginning, but much to be done. Commentary to Hutton et al. International Journal of Technology Assessment in Health Care 2007, 23:432-435.
17. IHS Global Insight NICE Rebuffs Kidney Cancer Drugs for Second Time Despite Offers of Price-Sharing Agreements 2009.
18. Dagher R., Johnson J., Williams G., Keegan P., Pazdur R. Accelerated approval of oncology products: a decade of experience. Journal of the National Cancer Institute 2004, 96:1500-1509.
19. Food and Drug Administration Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics 2007, US Department of Health and Human Services (Ed.).
20. Chalkidou K. " Only in research": a polite " no" or a valuable policy option?. NICE 2006: Tackling Health Priorities 2006, Birmingham, UK, NICE.
21. Anell A., Persson U. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?. The European Journal of Health Economics 2005, 6:274-279.
22. National Institute for Health and Clinical Excellence Rituximab for aggressive non-Hodgkin's lymphoma 2003, National Health Service.
23. Wlodarczyk J.H., Cleland L.G., Keogh A.M., McNeil K.D., Perl K., Weintraub R.G., et al. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing. PharmacoEconomics 2006, 24:903-915.
24. Chalkidou K., Hoy A., Littlejohns P. Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research. Journal of the Royal Society of Medicine 2007, 100:453-460.
25. Jönsson MI, Jönsson L. Decisions by the Swedish Pharmaceutical Benefits Board 2006-2008; in preparation.
26. Berns J.S., Fishbane S., Elzein H., Lynn R.I., Deoreo P.B., Tharpe D.L., et al. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients. Hemodialysis International 2005, 9:255-263.
27. Australian Department of Health and Ageing Imatinib mesylate 2008.
28. Lu C.Y., Williams K.M., Day R.O. The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines. Australia and New Zealand Health Policy 2007, 4:2.
29. Ontario Health Authority Ministry of health and long term care. Handbook of limited use drug products 2005, Ontario Health Authority, Toronto.
30. Smith M.D., Ahern M.J. Pharmaceutical Benefits Scheme criteria for the use of tumour necrosis factor-alpha inhibitors in the treatment of ankylosing spondylitis in Australia: are they evidence based?. Internal Medicine Journal 2006, 36:72-76.
31. Green C., Bryant J., Takeda A., Cooper K. Bortezomib for the treatment of multiple myeloma patients 2006, Southampton Health Technology Assessments Centre, University of Southampton.
32. Sparrowhawk K. Commentary: NICE (National Institute for health and Clinical Excellence) shares risk with the drug industry. SCRIP-World Pharmaceutical News 2007, 6.
33. IMS Health Inc. Contracting, rebating, risk-sharing-IMS conference hears about more innovative approaches to pricing 2007.
34. Moss L. New cancer drugs on NHS after price deal 2009.
35. Wagstaff A. Health rationing in Europe: can cancer get a fair hearing?. Cancer World 2009, 24-31.
36. Moldrup C. No cure, no pay. British Medical Journal (Clinical Research Edition) 2005, 330:1262-1264.
37. Chapman S., Reeve E., Rajaratnam G., Neary R. Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care. British Medical Journal (Clinical Research Edition) 2003, 326:707-709.
38. Anonymous Kritik an Rabatten auf Innovationen 2008, Apotheker Zeitung.
39. Thomson D. Position statement on " Risk Sharing" schemes in oncology 2008.
40. Pollack A. Drug deals tie prices to how well patients do. New York Times 2009.